Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.60 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15252779 | 0.89 | DGAT1 (0.46) | DGAT1LMNATRPV1POLBTHRB | |
| SCHEMBL1251668 | 0.89 | DGAT1 (0.77) | DGAT1LMNAPOLBMAPTRAB9A | |
| SCHEMBL1251610 | 0.89 | DGAT1 (0.77) | DGAT1LMNATRPV1POLBMAPT | |
| SCHEMBL1251408 | 0.88 | DGAT1 (0.66) | DGAT1RPS6KA2LMNATRPV1POLB | |
| SCHEMBL1250424 | 0.87 | DGAT1 (0.65) | DGAT1LMNATRPV1POLBMAPT | |
| SCHEMBL1250286 | 0.86 | DGAT1 (0.64) | DGAT1LMNATRPV1POLBMAPT | |
| SCHEMBL1250680 | 0.86 | DGAT1 (0.64) | DGAT1LMNATRPV1POLBMAPT | |
| SCHEMBL1251312 | 0.82 | DGAT1 (0.75) | DGAT1LMNAPOLBMAPTRAB9A | |
| SCHEMBL3168092 | 0.82 | DGAT1 (0.56) | DGAT1RAB9AHDAC3HDAC7HDAC6 | |
| SCHEMBL1248433 | 0.81 | DGAT1 (0.60) | DGAT1RPS6KA2LMNATRPV1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
| US-20110046133-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046133-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885RPS6KA2 4277/4885LMNA 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.